在AD小鼠模型中,ApoE导向的治疗方法快速清除β-粉样蛋白和逆转缺陷
Paige E Cramer1, John R Cirrito, Daniel W Wesson
1Department of Neurosciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Science (New York, N.Y.)
|February 11, 2012
概括
在阿尔茨海默氏病模型中,使用贝克萨罗激活RXR可增强大脑粉样β清除. 这种治疗通过刺激依赖apoE的清除机制,迅速扭转认知和社会缺陷.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 阿尔茨海默病 (AD) 涉及大脑粉样β (Aβ) 清除受损,这是由阿波利波蛋白E (apoE) 介导的过程.
- ApoE表达受到核受体的调节,包括视网膜X受体 (RXRs).
研究的目的:
- 在阿尔茨海默病小鼠模型中研究使用贝克萨罗激活RXRs的治疗潜力.
- 为了确定贝克萨罗是否增强了Aβ清除,并扭转了与AD相关的缺陷.
主要方法:
- 在AD的小鼠模型中,口服RXR激活剂贝克萨罗.
- 评估可溶性Aβ水平,Aβ斑块区域,认知功能,社会行为,嗅觉缺陷和神经电路活动.
主要成果:
- 贝克萨洛治疗导致可溶性Aβ在数小时内以一种ApoE-依赖的方式增强清除.
- 在72小时内,Aβ斑块面积显著减少了50%以上.
- 贝克萨罗迅速扭转了认知,社会和嗅觉缺陷,并改善了神经电路功能.
结论:
- 视网膜X受体 (RXR) 的激活刺激了内源性Aβ清除机制.
- 贝克萨罗为阿尔茨海默病提供了一个有前途的治疗策略,通过促进Aβ清除和逆转相关的缺陷.
更多相关视频
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
相关概念视频
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...